Real-world effectiveness and tolerability of dupilumab in adult atopic dermatitis

Abstract

Dupilumab (Dupixent®) is the first biologic drug licensed for treatment of adults with atopic dermatitis (AD). Data regarding its long‐term real‐world effectiveness and tolerability are limited.

We report comprehensive outcome data at one year for the first 100 adult patients initiated on dupilumab in a specialist eczema clinic (May 2017‐November 2019). In this prospective, observational cohort study (HRA UK ref.268527) all patients received dupilumab at licenced dose. Wherever possible, patients on other systemic treatment(s) underwent 4‐week washout prior to dupilumab. All patients were given preservative‐free lubricating eye ointment prior to dupilumab in view of ophthalmic complications reported in trials1‐3. Disease activity and patient‐reported outcome measures were assessed at baseline, week 12, week 24 and 1 year of treatment. Adverse events (AE) were recorded and classified4.